DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

March 1, 2006

FILE COPY

Stephen A. Campbell, Esq.
Senior Vice President, Regulatory Affairs
Amphastar Pharmaceuticals, Inc.
11570 6th Street
Ranch Cucamonga, CA 91730

Dear Mr. Campbell:

Your petition requesting the Food and Drug Administration to determine that Astra Zeneca's Diprivan, Teva Sicor's Propofol Injectable Emulsion, and Bedford Laboratories Propofol Injectable Emulsion are misbranded was received by this office on 03/01/06. It was assigned docket number 2006P-0092/CP1 and it was filed on 03/01/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Division of Dockets Management
Office of Management Programs
Office of Management

2006P-0092

ACK 1